Equillium, Inc.
NASDAQ:EQBiotechnology
+$0.05 today
- Market cap
- $90.56M
- Beta
- 1.76
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.20
Volume 0.89M
Average 0.60M
EQ Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Equillium, Inc.NASDAQ: EQ
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $35.35M rose 38741.8% year over year, ahead of the +25657.6% change in trailing-twelve-month financing cash flow. Sequentially, it rose 12389.8% from the prior quarter.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +38741.8% holds above the trailing-twelve-month pace of +25657.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 30.43M USD
- Year-over-year change
- +18453.0%
- 4-year CAGR
- -0.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.43M | +18453.0% |
| FY2024 | 2024-12-31 | 164K | +101.8% |
| FY2023 | 2023-12-31 | (9.23M) | -659.5% |
| FY2022 | 2022-12-31 | (1.22M) | -103.9% |
| FY2021 | 2021-12-31 | 31.06M | — |
Financing Cash Flow vs competitors
How EQ compares with its peers on the latest reported figures
- EQ's LTM Mar 2026 financing cash flow of $65.68M is the 2nd largest of the 10 companies compared; the peer median is $19.12M.
- Its year-over-year change of +25657.6% is the highest of 10, against a peer median of +93.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $126.68M | +124.3% | -81.5% | — | |
| LTM Mar 2026 | $65.68M | +25657.6% | — | — | |
| LTM Mar 2026 | $57.81M | +3300.9% | — | — | |
| LTM Mar 2026 | $47.24M | +93.8% | -8.9% | 14179.4% | |
| LTM Mar 2026 | $27.6M | +300.6% | -21.2% | 84.3% | |
| LTM Mar 2026 | $19.12M | +27.6% | -10.3% | 833.6% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $13.6M | +3.6% | +1272.4% | — |
| LTM Mar 2026 | $9.76M | +768.9% | +174.4% | — | |
| LTM Mar 2026 | $8.35M | -18.6% | +35.8% | 590.3% | |
| LTM Mar 2026 | $2.09M | -102.2% | +0.9% | 3.2% | |
| Peer median (excluding EQ) | $19.12M | +93.8% | -4.0% | 590.3% | |
Competitors are the stored peer set for EQ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (39.05M) | (62.43M) | (13.34M) | (8.07M) | (22.4M) |
| Depreciation & Amortization | 72K | 118K | 126K | 137K | 116K |
| Deferred Income Tax | 554K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.41M | 4.84M | 4M | 3.75M | 2.32M |
| Change in Working Capital | 1.7M | 19K | (2.55M) | 842K | (2.32M) |
| Accounts Receivables | 0 | (2.84M) | (897K) | 3.74M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.58M) | 2.51M | 723K | (2M) | (1.94M) |
| Other Working Capital | 3.28M | 349K | (2.37M) | (898K) | (380K) |
| Other Non-Cash Items | 237K | 48.72M | (10.03M) | (15.69M) | (469K) |
| Operating Cash Flow | (32.08M) | (8.73M) | (21.78M) | (19.03M) | (22.75M) |
| Capital Expenditures | (57K) | (279K) | (50K) | (85K) | (48K) |
| Acquisitions (Net) | 0 | 700K | 0 | 0 | 12K |
| Purchases of Investments | (32.99M) | (14.96M) | (54.71M) | (17.6M) | 0 |
| Sales of Investments | 60.46M | 33.23M | 50M | 31.5M | 4.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 27.41M | 18.68M | (4.76M) | 13.81M | 4.46M |
| Debt Repayment | 0 | (1.43M) | (9.13M) | 0 | 0 |
| Common Stock Issued | 29.91M | 214K | 0 | 164K | 30.43M |
| Common Stock Repurchased | 0 | 0 | (260K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.15M | 0 | 165K | 0 | 0 |
| Financing Cash Flow | 31.06M | (1.22M) | (9.23M) | 164K | 30.43M |
| Effect of Forex Changes | (2K) | 5K | (118K) | (83K) | 47K |
| Net Change in Cash | 26.38M | 8.74M | (35.89M) | (5.13M) | 12.19M |
| Free Cash Flow | (32.14M) | (9.01M) | (21.83M) | (19.11M) | (22.79M) |
Equillium, Inc.
NASDAQ:EQ
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.